APA (7th ed.) Citation

Zhao, W., Liu, J., Wang, B., Chen, Y., Cao, X., Yang, Y., . . . Zhang, W. (2018). A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. Journal of hematology and oncology, 11(1), 141-8. https://doi.org/10.1186/s13045-018-0681-6

Chicago Style (17th ed.) Citation

Zhao, Wan-Hong, et al. "A Phase 1, Open-label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma." Journal of Hematology and Oncology 11, no. 1 (2018): 141-8. https://doi.org/10.1186/s13045-018-0681-6.

MLA (9th ed.) Citation

Zhao, Wan-Hong, et al. "A Phase 1, Open-label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma." Journal of Hematology and Oncology, vol. 11, no. 1, 2018, pp. 141-8, https://doi.org/10.1186/s13045-018-0681-6.